Patras

• A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S … Ended
  2023-505786-88-00 5 2021-04-25 Severe and inadequately controlled asthma
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation … Ended
  2023-507222-17-00 5 2020-07-24 Acute Myeloid Leukaemia
• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer Ended
  2023-507148-35-00 5 2019-10-03 Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastroint
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca

Showing 217–226 of 226 trials